- $285.33m
- $700.73m
- $724.34m
- 66
- 99
- 23
- 67
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.6 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 2.79 | ||
| Price to Sales | 0.39 | ||
| EV to EBITDA | 4.32 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.61% | ||
| Return on Equity | -15.18% | ||
| Operating Margin | 14.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 476.25 | 821.68 | 842.68 | 770.88 | 724.34 | 696.45 | 719.3 | 41.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cresco Labs Inc. is an integrated multi-state cannabis operator in the United States. The Company is licensed to cultivate, manufacture, and sell retail and medical cannabis products primarily through Sunnyside, Cresco Labs’ national dispensary brand, and third-party retail stores. Its family brands include Cresco, High Supply, Good News, Wonder Wellness Co., FloraCal Farms, Remedi and Mindy’s. Its portfolio consists of over 500 products. Its products are sold in over 1,400 dispensaries across the country. Cresco offers flower, liquid live resin vapes and concentrates available in a variety of product forms at dispensaries and retail locations. Its High Supply is lab-tested, and available in vape carts, vape pens, flowers, popcorn, shakes, shorties, and concentrates. Its Remedi products provide a consistent and trusted alternative to traditional pharmaceuticals like opioids. Mindy’s offers dosed edibles created by James Beard. It is the wholesaler of branded cannabis products.
Directors
- Thomas Manning CHM (64)
- Charles Bachtell CEO (42)
- Dennis Olis CFO (58)
- Ty Gent COO (61)
- John Schetz GCN (44)
- Marc Lustig OTH (47)
- Gregory Butler OTH (41)
- Robert Sampson DRC (47)
- Tarik Brooks IND
- Gerald Corcoran IND (65)
- Sidney Dillard IND
- Randy Podolsky IND (65)
- Michele Roberts IND (64)
- Dominic Sergi IND (37)
- Carol Vallone IND (64)
- John Walter IND (73)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 6th, 1990
- Public Since
- December 3rd, 2018
- No. of Employees
- 2,900
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 443,956,271
- Address
- 600 W. FULTON STREET, SUITE 800, CHICAGO, 60661
- Web
- https://www.crescolabs.com/
- Phone
- +1 3129290993
- Auditors
- Marcum LLP
Upcoming Events for CRLBF
Cresco Labs Inc Annual Shareholders Meeting
Q2 2025 Cresco Labs Inc Earnings Release
Similar to CRLBF
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Cresco Labs share price?
As of Today at 20:06 UTC, shares in Cresco Labs are trading at $0.67. This share price information is delayed by 15 minutes.
How has the Cresco Labs share price performed this year?
Shares in Cresco Labs last closed at $0.67 and the price had moved by -69.5% over the past 365 days. In terms of relative price strength the Cresco Labs share price has underperformed the S&P500 Index by -71.18% over the past year.
What are the analyst and broker recommendations for Cresco Labs?
The overall consensus recommendation for Cresco Labs is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cresco Labs dividend yield?
Cresco Labs does not currently pay a dividend.
Does Cresco Labs pay a dividend?
Cresco Labs does not currently pay a dividend.
When does Cresco Labs next pay dividends?
Cresco Labs does not currently pay a dividend.
How do I buy Cresco Labs shares?
To buy shares in Cresco Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cresco Labs?
As of the previous close price of $0.67, shares in Cresco Labs had a market capitalisation of $285.33m.
Where are Cresco Labs shares listed?
Here are the trading details for Cresco Labs:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CRLBF
What kind of share is Cresco Labs?
Based on an overall assessment of its quality, value and momentum Cresco Labs is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cresco Labs share price forecast for 2025?
The analyst consensus target price for shares in Cresco Labs is $2.98. That is 345.75% above the last closing price of $0.67.
Analysts covering Cresco Labs currently have a consensus Earnings Per Share (EPS) forecast of -$0.11 for the next financial year.
Find out moreWhat is the trend in the Cresco Labs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cresco Labs. Over the past six months, its share price has underperformed the S&P500 Index by -54.63%.
As of the last closing price of $0.67, shares in Cresco Labs were trading -45.9% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cresco Labs PE Ratio?
The Cresco Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cresco Labs?
Cresco Labs' management team is headed by:
- Thomas Manning - CHM
- Charles Bachtell - CEO
- Dennis Olis - CFO
- Ty Gent - COO
- John Schetz - GCN
- Marc Lustig - OTH
- Gregory Butler - OTH
- Robert Sampson - DRC
- Tarik Brooks - IND
- Gerald Corcoran - IND
- Sidney Dillard - IND
- Randy Podolsky - IND
- Michele Roberts - IND
- Dominic Sergi - IND
- Carol Vallone - IND
- John Walter - IND